4-碘-2,5-二甲氧基-α-甲基苯甲胺 | 64584-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-碘-2,5-二甲氧基-α-甲基苯甲胺
• 中文别名: 4-碘-2,5-二甲氧基-Α-甲基苯甲胺
• 英文名称: 4-iodo-2,5-dimethoxyphenylisopropylamine
• 英文别名: 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane；1-(4-Iodo-2,5-dimethoxyphenyl)propan-2-amine
• CAS: 64584-34-5
• 化学式: C₁₁H₁₆INO₂
• 分子量: 321.158
• InChiKey: BGMZUEKZENQUJY-UHFFFAOYSA-N

物化性质

• 沸点：
  361.5±42.0 °C(Predicted)
• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-碘-2,5-二甲氧基-α-甲基苯甲胺 生成 (+)-DOI
  参考文献：
  名称：

  5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs

  摘要：

  1-(2,5-Dimethoxy-4-bromophenyl)-2-aminopropane (DOB; 1a) is a purported serotonin (5-HT) agonist that binds selectively to central 5-HT2 binding sites. Systematic removal of any or all of the aromatic substituents had relatively little effect on 5-HT1 binding but reduced 5-HT2 binding by approximately 2 or more orders of magnitude. Demethylation of the 2-methoxy group of 1a, or introduction of an N-n-propyl group, doubled 5-HT1-site affinity but decreased 5-HT2-site affinity by 3- and 30-fold, respectively. In tests of stimulus generalization, using rats trained to discriminate DOM from saline, the 2-demethyl and N-propyl derivatives were found to produce stimulus effects similar to those of DOB. In addition, the S-(+) isomer of the iodo analogue of 1a was found to possess one-third the affinity of its R-(-) enantiomer at 5-HT2 sites and also resulted in DOM-stimulus generalization. Of the DOB analogues examined, DOB (1a) possesses optimal selectivity for 5-HT2 binding.

  DOI：

  10.1021/jm00152a005
• 作为产物：
  描述：

  2-氨基-4-苯基丙烷盐酸盐 在 碘 、 silver sulfate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以78%的产率得到4-碘-2,5-二甲氧基-α-甲基苯甲胺
  参考文献：
  名称：

  Iodination of methoxyamphetamines with iodine and silver sulfate.

  摘要：

  DOI：

  10.1016/s0040-4039(00)73715-4

文献信息

• [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
  申请人：REDX PHARMA PLC

  公开号：WO2016051193A1

  公开（公告）日：2016-04-07

  This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

  这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地，该发明涉及用作集落刺激因子1受体（cFMS）调节剂（例如cFMS抑制剂）的化合物。这项发明还涉及制备这些化合物的方法，这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言，该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
• [EN] CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE<br/>[FR] PROMÉDICAMENTS DE CARBAMATE DE CATÉCHOLAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：H LUNDBECK AS

  公开号：WO2020234277A1

  公开（公告）日：2020-11-26

  The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

  本发明提供了化合物的公式（Id），这些化合物是儿茶酚胺的前药，用于治疗神经退行性疾病和紊乱。本发明还提供了包括本发明化合物的药物组合物，以及使用本发明化合物治疗神经退行性或神经精神疾病和紊乱的方法，特别是帕金森病。
• [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：REDX PHARMA PLC

  公开号：WO2017103611A1

  公开（公告）日：2017-06-22

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说，该发明的化合物可用作布鲁顿氏酪氨酸激酶（BTK）的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS N-PYRIDINYL ACÉTAMIDE COMME INHIBITEURS DE LA OIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055790A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。
• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY<br/>[FR] DÉRIVÉS DE N-PYRIDYL ACÉTAMIDE UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055786A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。

表征谱图